69 completed, 12 terminated, 8 unknown, 6 recruiting. 100 Phase 1, 25 Phase 2.
Follow Chronic Obstructive Pulmonary Disease: new trials by email Literature Review of Chronic Obstructive Pulmonary Disease trials Research Report on Chronic Obstructive Pulmonary Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD Inhaled Nitric Oxide, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Not yet recruiting | University of Alberta | 80 | 2026-12-01 | 2026-07-08 |
| A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects TQC3302 inhalation spray, TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation, Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | 33 | 2025-11-25 | 2026-08-27 |
| The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations XH-S004 20 mg, 40 mg or 60 mg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 81 | 2025-07-15 | 2026-09-25 |
| A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) BBT002, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Recruiting | Bambusa Therapeutics | 286 | 2025-05-08 | 2026-07-01 |
| A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 48 | 2025-02-11 | 2025-08-15 |
| Evaluation the Safety of hemay005 Tablets Hemay005 tablet, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Anhui Hemay Pharmaceutical Co., Ltd | 468 | 2024-12-25 | 2025-12-09 |
| A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease GDC-6988 - Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Genentech, Inc. | 17 | 2024-11-18 | 2026-10-20 |
| A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2024-05-22 | 2024-10-29 |
| A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | AstraZeneca | 42 | 2024-04-29 | 2025-08-13 |
| Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers CHF6001 DPI, Erythromycin - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 24 | 2024-03-28 | 2024-07-03 |
| Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler - Chronic Obstructive Pulmonary Disease | Phase 1 | Active not recruiting | Polarean, Inc. | 6 | 2024-03-19 | 2026-10-27 |
| A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot) Tiotropium Bromide Inhalation Powder, Spiriva HandiHaler - Chronic Obstructive Pulmonary Disease | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 39 | 2024-02-28 | 2024-03-29 |
| Feasibility of Semaglutide in Advanced Lung Disease Semaglutide Pen Injector - Obesity, Interstitial Lung Disease | Phase 1 / Phase 2 | Recruiting | University of Pennsylvania | 8 | 2024-01-29 | 2026-04-21 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects Ensifentrine - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Nuance Pharma (shanghai) Co., Ltd | 28 | 2023-03-06 | 2023-04-24 |
| Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients HRS-9821 - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 106 | 2023-01-12 | 2025-07-24 |
| A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | AstraZeneca | 108 | 2022-10-11 | 2025-08-22 |
| Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults EP395, Placebo - Chronic Obstructive Pulmonary Disease, COPD | Phase 1 | Completed | EpiEndo Pharmaceuticals | 49 | 2022-10-11 | 2026-04-29 |
| PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers CH6001 - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 44 | 2022-07-29 | 2023-01-26 |
| Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal) - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | AstraZeneca | 108 | 2022-07-29 | 2025-08-28 |
| Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease ARO-MUC5AC, Placebo - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 78 | 2022-06-27 | 2026-09-14 |
Showing 20 of 100. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (100) · Asthma (10) · Emphysema (4) · Lung Diseases (3) · Respiration Disorders (3) · Dyspnea (2) · Heart Failure (2) · Hypertension, Pulmonary (2) · Idiopathic Pulmonary Fibrosis (2) · Bronchiolitis (1) · Bronchiolitis Obliterans Syndrome (1) · Bronchitis, Chronic (1) · COVID-19 (1) · Cardiovascular Diseases (1) · Cough (1)
Chronic Disease (100) · Disease Attributes (100) · Pathologic Processes (100) · Pathological Conditions, Signs and Symptoms (100) · Respiratory Tract Diseases (100) · Lung Diseases, Obstructive (99) · Lung Diseases (97) · Bronchial Diseases (13) · Immune System Diseases (12) · Hypersensitivity (11) · Hypersensitivity, Immediate (10) · Respiratory Hypersensitivity (10) · Cardiovascular Diseases (4) · Respiration Disorders (4) · Signs and Symptoms (4)
Inhalation (5) · Budesonide (4) · Moxifloxacin (3) · Tiotropium Bromide (3) · Cyclosporine (2) · Glycopyrrolate (2) · N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide (2) · Quercetin (2) · bedoradrine (2) · tanimilast (2) · 2-hydroxy-N,N-dimethyl-3-(2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-enylamino)benzamide (1) · 5-(2-((6-(2,2-difluoro-2-phenylethoxy)hexyl)amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one (1) · 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide (1) · AZD-3199 (1) · AZD-8871 (1)
AstraZeneca (14) · Chiesi Farmaceutici S.p.A. (11) · Pearl Therapeutics, Inc. (5) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (4) · Novartis (3) · Gilead Sciences (2) · Mayo Clinic (2) · MediciNova (2) · Novartis Pharmaceuticals (2) · Acusphere (1) · Aeris Therapeutics (1) · Ageless Regenerative Institute (1) · Air Liquide SA (1) · Alexza Pharmaceuticals, Inc. (1) · Amgen (1)
United States (37) · United Kingdom (18) · China (13) · Germany (12) · Australia (5) · Belgium (4) · New Zealand (4) · Bulgaria (3) · Brazil (2) · France (2) · Poland (2) · Georgia (1) · Greece (1) · Israel (1) · Netherlands (1)
Stuart Mair, MD (3) · Colin Reisner, M.D. (2) · Dave Singh, MD (2) · Emma Harrop (2) · Michael Donahoe, MD (2) · Paul M. Dorinsky, MD (2) · Rainard Fuhr (2) · Alan W Dunton, MD (1) · Ashika Ahmed (1) · Carin Jorup, MD (1)
PMID 40391696, PMID 41677208, PMID 12543832, PMID 16611654, PMID 19436683, PMID 19643947, PMID 20920189, PMID 21474911, PMID 21615886, PMID 22075481, PMID 22465313, PMID 22793945, PMID 22927751, PMID 24168756, PMID 25027304, PMID 25060541, PMID 25383540, PMID 25526796, PMID 26050967, PMID 26341216, PMID 26493806, PMID 27736154, PMID 28128970, PMID 28691311, PMID 28702957, PMID 28860265, PMID 29856004, PMID 29975735, PMID 30425469, PMID 30982547, PMID 31125359, PMID 31539289, PMID 31841699, PMID 32071149, PMID 32253054, PMID 32907575, PMID 33152467, PMID 33511633, PMID 34600734, PMID 34620167, PMID 35128939, PMID 37546740, PMID 38468259, PMID 40466859
2015 (2), 2018 (2), 2023 (2), 2008 (1), 2009 (1), 2014 (1), 2016 (1), 2017 (1), 2019 (1), R01HL096471 (1), R21AT007357 (1), R33AT009991 (1)